Patent Number: 7,087,573

Title: Methods of inhibiting platelet anti-HLA alloimmune antibody responses with soluble 18 KDa CD40L

Abstract: The invention relates to a method for inhibiting an in vivo alloimmune response, and to the use of a soluble recombinant human CD40L protein containing the active binding site with CD40. In particular, a soluble 18 KDa recombinant CD40L is used to inhibit an in vivo alloimmune response.

Inventors: Lazarus; Alan H. (Toronto, CA), Crow; Andrew R. (East York, CA), Freedman; John (Toronto, CA)

Assignee: Canadian Blood Services

International Classification: A61K 38/16 (20060101); A61K 38/19 (20060101)

Expiration Date: 8/08/02018